Showing results (311-320 of 348) with videos related to

Sort By:
Pageof 35
Cancer Immunology, Immunotherapy : CII|May 11, 2023
Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12S Elizabeth Franks, Ginette S Santiago-Sanchez, Kellsye P Fabian, et al.
Cancer Immunology Research|April 30, 2014
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancerJames L Gulley, Ravi A Madan, Kwong Y Tsang, et al.
Frontiers in Immunology|June 19, 2026
Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer modelsJonelle K Lee, Kellsye P Fabian, Ginette S Santiago-Sanchez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2019
Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer TherapyKristin C Hicks, Karin M Knudson, Karin L Lee, et al.
International Journal of Cancer|March 4, 2000
Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicityY R Freund, J C Mirsalis, D G Fairchild, et al.
AIDS Research and Human Retroviruses|March 13, 2012
Identification of cellular proteins required for replication of human immunodeficiency virus type 1Natallia Dziuba, Monique R Ferguson, William A O'Brien, et al.
Neuron|February 17, 2000
A novel nociceptor signaling pathway revealed in protein kinase C epsilon mutant miceS G Khasar, Y H Lin, A Martin, et al.
Oncoimmunology|November 1, 2018
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell typesKristin C Hicks, Massimo Fantini, Renee N Donahue, et al.
Frontiers in Oncology|May 14, 2024
Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrenceDiana C Lopez, Kellsye P Fabian, Michelle R Padget, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2019
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T CellsJay Friedman, Ellen C Moore, Paul Zolkind, et al.
Pageof 35